Salt Composition in both
Salt Composition
Sildenafil 25mg(same for both)
You Searched
Strip of 10 tablets
We only sell the best substitute from top brands
Our Recommendation
Suhagra 25mg Tablet 4s
Strip of 4 tablets
3,210+ Customers trust this
WHO GMP Certified
Marketed by
Doctor ApprovedMedicine Comparison
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.
Pantosec DSR 30/40mg PR Capsule 10sPantosec 40mg Tablet 10sCipvildin M 500/50mg Tablet 15sAb Rozu 10mg Tablet 10sCipcal D3 60000IU Capsule 4sCipcal 500mg/250IU Tablet 15sDapaquest 10mg Tablet 10sMontecip LC 5/10mg Tablet 10sLipvas 10mg Tablet 10sParacip 650mg Tablet 10sView More
Aerolife inhalation Device 1sAir Space Wit Exhle Valve Device 1sBp Monitor (Omron) Hem 8712 Device 1sContour Plus System 1sDigital Thermometer Mercury Device 1sDuohaler DPI Device 1sIbreathe DPI Inhealer Device 1sMachaler DPI Device 1sMacspacer Device 1sNovopen 4 | Diabetes Monitoring Devices 1s
Submit your drugsA registered doctor can review the following information:
Lithium 24-hour remember?This is a single-dose tablet. Always follow your doctor's instructions and dosages. Check your blood pressure before taking this or any other dose.
GlaxoSmithKline (GSK) is looking to get a licence to sell Viagra for over 18 years.
The company, which has more than 20 years of marketing experience in the pharmaceutical industry, is looking to get licence to sell Viagra for over 18 years.
GSK, which is one of the world’s largest pharmaceutical companies, is set to give the green light to a company selling Viagra for over 18 years to produce a generic version of Pfizer’s blockbuster Viagra.
GSK has already said it will take the company’s product to a ‘patent cliff’. The company, which has more than 20 years of marketing experience in the pharmaceutical industry, will also have to stop producing Viagra on the NHS after the pharmaceutical company, Pfizer, announced it was losing its patent protection.
It has also said it will stop marketing the drug to patients by the end of this year.
GSK said that the product is currently not ready for generic production and could be sold as Viagra by some companies.
“This patent will give us a huge opportunity to expand the pharmaceutical market and we will not stop marketing Viagra. This will enable us to launch our Viagra in many other markets without having to take any risk in the pharmaceutical industry.”
GSK said that the company had already been granted a “patent cliff”.
“GSK’s patent will go into effect after the end of this year, so we have a huge opportunity to launch our Viagra and to be able to sell it on the NHS. This will allow us to launch our Viagra in a more reliable and accessible way than the alternatives.
“We are also looking to build our sales force, which will be very strong in the coming years, so we are looking to grow as a pharmaceutical company.”
GSK is based in the UK and has a manufacturing facility in Bristol, the US, and in Ireland.
GSK is also based in India and is involved in the sale of medicines in other countries.
GSK sales of Viagra12GSK is based in the UK and has a manufacturing facility in Bristol.
3
GSK has a manufacturing facility in the UK and is involved in the sale of medicines in other countries.
4
GSK is based in the UK and has a manufacturing facility in the US.
GSK’s annual sales of Viagra are up 2% year over year compared to last year.
GSK, which is based in Bristol, said it is now “staying on track” to generate annual sales of £1.1bn for the year.
The company is one of the world's largest drug manufacturers and is responsible for producing over 70 medicinal products.
GSK is one of the world's largest pharmaceutical companies, having an active and focused corporate unit in manufacturing and research.
GSK is one of the world's largest drug manufacturers and is responsible for producing over 70 medicinal products.
GSK is one of the world's largest drug manufacturers, having an active and focused corporate unit in manufacturing and research.
GSK was one of the world's largest drug manufacturers and is responsible for producing over 70 medicinal products.
GSK has been at the centre of a global crisis that has forced the UK government to step in to negotiate with the pharmaceutical industry over the supply of erectile dysfunction drugs.
The drug supply deal was negotiated in December 2014 and was set to take place in late 2015.
5GSK has an active and focused corporate unit in manufacturing and research.
Viagra has been shown to cause some mild side effects. Talk to your health care provider if these do not go away within a few days. If you begin to experience more serious reactions, seek medical attention immediately.
Common side effects reported from Viagra use include:
More severe side effects include:
If you experience any of these side effects, seek medical attention immediately. These are symptoms of a severe adverse reaction to this medication that require immediate treatment.
As with all prescription medications, inform your doctor of any medical conditions you currently manage. Tell them about any and all medications, prescription drugs, and supplements you are taking before starting treatment with Viagra. Viagra can interact with bodily substances, causing potentially serious adverse reactions.
Specifically, you should inform your health care provider of any nitrate medication you are taking. Remember to mention any herbal products you use, especially St. John’s wort.
In addition, let your doctor know if you have recently had heart surgery or experience chest pain during sex. If you experience any changes in your heartbeat or chest pain during sex, contact your health care provider immediately.
asthma is a medication used to treat symptoms of a heart attack or stroke. To report adverse events following an heart attack or stroke, contact their via the.Objective:This is a prospective, randomized, parallel, double-blind, placebo-controlled study evaluating the efficacy and safety of sildenafil (Viagra) in men with mild-to-moderate to severe erectile dysfunction.
Design:A single-centre, open-label, 3-period study of sildenafil (1 mg/day) in patients with mild-to-moderate to severe erectile dysfunction.
Setting:U. S. centers. Study group: Men who are at least 40 years old and willing to undergo a 4-week study of treatment with sildenafil. Group 1 included men with mild-to-moderate ED (defined as male to female ratio 4:1, defined as the mean age of 50 years), with a normal ED (male to female ratio 3:1, defined as the mean age of 65 years) and with normal ED (male to female ratio 1:1, defined as the mean age of 65 years).Method:After a 4-week washout, the primary outcome was the change from baseline to week 3, secondary outcome was change from baseline to week 6, and treatment assignment was made on week 6. Sildenafil was evaluated in a randomized, double-blind, placebo-controlled trial.
Main outcome measure:The primary outcome measure was the change from baseline to week 3. Secondary outcomes included the change from baseline to week 6, the change from baseline to week 6, and any clinical benefit.
Results:The primary outcome measure was the change from baseline to week 3 in the primary efficacy variable (sildenafil efficacy or efficacy endpoint), the change from baseline to week 3, and any clinical benefit. The change from baseline to week 3 was significantly greater in patients with mild-to-severe ED than in patients with normal ED.
Conclusions:This study shows that sildenafil (Viagra) is a safe and effective treatment for mild-to-moderate to severe erectile dysfunction in patients with ED, and that it provides substantial improvements in overall and sexual function. It appears to be effective for improving erectile function in men with ED and that it is more effective than placebo in men with normal ED.
Viagra for erectile dysfunctionErectile dysfunction (ED) is a common condition that affects approximately 40 million men worldwide. It can cause significant distress and impairment in sexual performance. While there are several treatments for ED, there is little evidence for any of them. The goal of this study was to evaluate the efficacy and safety of sildenafil (Viagra) in the treatment of mild-to-severe erectile dysfunction.
Methods:The study was a 3-period, double-blind, placebo-controlled, multicentre, open-label, crossover study of sildenafil (1 mg/day) in patients with mild-to-severe ED (male to female ratio 2:1, defined as the mean age of 50 years). The study included a total of 45 men who had mild-to-severe ED (male to female ratio 2:1, defined as the mean age of 25 years) and 40 healthy men (male to female ratio 2:1, defined as the mean age of 70 years) who completed a 4-week washout period, with or without sexual activity. Sildenafil was administered in a dose of 1 mg/day. The study was conducted in accordance with the Declaration of Helsinki, the European Conference on Pharmacoepidemiology (C. E. P.), and the Guideline for the Safety of Medicines (G. M.).
The study design was designed by the American Society of Sexual Medicine (ASSM) and the American Society of Clinical Oncology (ASCO). This study was approved by the University of California Health Science Center Institutional Review Board (IRB: 14/H10/16).
Patients:
All patients who have received sildenafil (Viagra) for ED were included in the study.
Eligible patients: Patients who meet the following criteria were eligible:
1. Age 18 years, female:All men aged 18 years and older.
2. Age 25 years, female:All men aged 25 years and older.
3.
The European Union is taking steps to regulate the use of erectile dysfunction drugs, after a European health care regulator was called in to answer questions about its safety.
The European Commission on Wednesday confirmed it had taken a strong step against the use of erectile dysfunction drugs in Sweden. But health authorities in other countries are not allowed to prescribe the drugs.
The European Commission on Wednesday said it had taken a strong step against the use of erectile dysfunction drugs in Sweden.
The commission on Wednesday confirmed it had taken a strong step against the use of erectile dysfunction drugs in Sweden, a move that should have been the subject of a lengthy legal review.
The European Commission on Wednesday confirmed it had taken a strong step against the use of erectile dysfunction drugs in Sweden, a move that should have been the subject of a lengthy legal review.
The European Commission on Wednesday said it had taken a strong step against the use of erectile dysfunction drugs in Sweden, a move that should have been the subject of a lengthy legal review.
A number of European countries have already made changes to drug safety in the last 10 years. In Sweden, which is the biggest producer of Viagra in the world, a warning letter from the European Commission on Wednesday said it had taken a strong step against the use of erectile dysfunction drugs in its country of origin.
The letter said Viagra was the world's second-biggest drug, but only in the UK, which has already introduced Viagra.
The warning letter said the drug was "unapproved" for use in Sweden but had been given "no licence in the UK". It also said the drug was not approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of impotence.
Stade de France Pharmacy